Conferences - Results from #120

Viewing 121-140 of 11114 articles

EAU 2024: Which Future for Immunotherapy in Localized Kidney Cancer?

EAU 2024: Rapid Fire Debate 6: Patient with Non-Invasive, High Grade Upper Tract Disease in Setting of Prior Radical Cystectomy – What Is Optimal Management? What If GFR ~ 50 Instead of 80?

EAU 2024: Trial in Progress: SunRISe-3: TAR-200 plus Cetrelimab or TAR-200 Versus Intravesical BCG in Patients with BCG-Naive High-Risk Non–muscle-Invasive Bladder Cancer

EAU 2024: Validation of FGFR Screening by Uromonitor® and Therascreen in FFPE Tissue in Bladder Cancer in the Context of the Clinical-Pathological Real-World Registry Study "Bladder BRIDGister"

EAU 2024: Rapid Fire Debate 5: The Age-Old Debate – What Is the Best Treatment – Oncological and QoL – for Young Healthy Patient with MIBC? What About Health Care Related Costs?

Urine Test Halves Painful Procedures in Bladder Cancer Follow Up, New Trial Shows

Five-Year Interval Is Safe for Prostate Cancer Screening, Research Shows

EAU 2024: Risk Adapted Screening for Prostate Cancer in Europe: PSA Only - the PROBASE German Screening Trial in Young Men

EAU 2024: Development of the Bladder Utility Symptom Scale (BUSS Utility): A Novel Tool to Measure Utilities and Quality of Life in Bladder Cancer Patients

EAU 2024: Development and External Validation of an Artificial Intelligence-Based Tool for PROGression Risk Assessment in Non-Muscle Invasive Bladder Cancer: PROGRxN-BCa

EAU 2024: Rapid Fire Debate 4: Patient with MIBC After Radical Cystectomy – Can We Use ctDNA to Guide Decisions on Adjuvant Chemo/IO? What About utDNA for Bladder Sparing After NAC?

EAU 2024: Towards Defining Follow-up Strategies for Patients with Primary EAU 2021 Intermediate-Risk Non-Muscle Invasive Bladder Cancer

EAU 2024: Defining Intermediate-Risk Non-Muscle Invasive Bladder Cancer: A Comparative Study of EAU and IBCG Criteria

EAU 2024: Risk Adapted Screening for Prostate Cancer in Europe: MRI Only

EAU 2024: Rapid Fire Debate 3: Healthy Patient with T1HG Micropapillary NMIBC - What Is the Best Treatment Option? What If Mixed Histologic Subtypes in Addition to Micropapillary?

EAU 2024: European Urology Oncology Lecture: Survivorship Considerations Across the Spectrum of Genitourinary Oncology

EAU 2024: State-of-the-Art Lecture: Long-Term Toxicity in Testicular Cancer and AYA: Premature Mortality and Morbidity Illustrated

EAU 2024: Options and Challenges in the Management of Oligometastatic Prostate Cancer in the PSMA-PET Era

EAU 2024: Rapid Fire Debate 2: How Do We Manage a Patient with Frequent Recurrence of LG Papillary Tumours in the Bladder Despite Intravesical Chemotherapy and BCG Therapy? No Clinical Trial Available

EAU 2024: Extended Follow-up from CheckMate 274 Including the First Report of Overall Survival Outcomes

2
3
4
5
6
7
8
9
10
11